26,59,60 SGLT2i has the potential to treat MASH through four main mechanisms: decreasing hepatic de novo lipogenesis by lowering insulin levels, increasing fatty acid -oxidation by stimulating glucagon secretion, suppressing glucose-induced oxidative stress, and inhibiting liver fibrosis by lowering transforming growth factor-beta levels
Moses RG, Round E, Shentu Y et al (2016) A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
Description Retatrutide (GLP-3) 15mg is a synthetic triple receptor agonist peptide studied in preclinical and clinical research for its interactions with GLP-1, GIP, and glucagon receptor (GLP-1/GIP/GCGR) binding and downstream signaling pathway analysis
(2009) 296:E41521
Our pharmacy team helps employers strategically optimize their Rx spend without compromising care
The evidence STEP (NEJM 2021), SURMOUNT (NEJM 2022), SURMOUNT-OSA (NEJM 2024) attaches to the compound, not to the brand delivering it
